0001367644-26-000038
SEC filingEmergent BioSolutions entered a new $150M term loan and a $75M delayed draw facility, refinancing prior debt and amending its ABL facility to extend maturities to 2031 and reduce interest expense.
Emergent BioSolutions executed a comprehensive refinancing strategy to extend its debt maturities and reduce interest expenses. The company entered into a new Term Loan Agreement with OrbiMed Royalty & Credit Opportunities V, LP, securing $150 million in immediate liquidity and a $75 million delayed draw facility. The proceeds were used to fully repay and terminate the Prior Credit Agreement with Oak Hill Advisors, dated August 30, 2024. This transaction successfully extends the maturity profile to April 2031 for both the new Term Loan and the amended ABL facility. The press release highlights a 200 basis point reduction in annual interest expense on the Term Loan, which carries a coupon of Term SOFR plus 6.25% with a 3.00% floor. Concurrently, the company amended its ABL facility with Wells Fargo, reducing the commitment from $100 million to $50 million while aligning the maturity with the new Term Loan. The new agreements introduce a consolidated total leverage ratio covenant of 5.25:1.00, commencing with the fiscal quarter ending September 30, 2026. The structure also provides enhanced financial flexibility through an uncommitted incremental facility and a delayed draw term loan, positioning the company to pursue strategic initiatives as part of its multi-year transformation plan.